Medscape InDiscussion: Schizophrenia

Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://emedicine.medscape.com/article/288259-overview

MDMA for the Treatment of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/35743326/

MDMA (Ecstasy/Molly) https://nida.nih.gov/publications/drugfacts/mdma-ecstasymolly

The NIMH-MATRICS Consensus Statement on Negative Symptoms https://pubmed.ncbi.nlm.nih.gov/16481659/

The Current Conceptualization of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/28127915/

Akinesia https://www.ncbi.nlm.nih.gov/books/NBK562177/

An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) Commonly Used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS) https://pubmed.ncbi.nlm.nih.gov/29430333/

Ecological Momentary Assessment https://pubmed.ncbi.nlm.nih.gov/18509902/

Schizophrenia Medication https://emedicine.medscape.com/article/288259-medication#2

Cariprazine, a Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety https://pubmed.ncbi.nlm.nih.gov/34091867/

DRD3 Dopamine Receptor D3 [Homo sapiens (human)] https://www.ncbi.nlm.nih.gov/gene/1814

MDA https://dictionary.apa.org/mda

Transcranial Magnetic Stimulation: A Review of Its Evolution and Current Applications https://pubmed.ncbi.nlm.nih.gov/31359968/

Memantine https://www.ncbi.nlm.nih.gov/books/NBK500025/

Making MDMA a Medicine (II) (Re)scheduling for Schedule I Substances https://maps.org/news/bulletin/making-mdma-a-medicine-ii-rescheduling-for-schedule-1-substances/

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK548187/

Metaplasticity: Tuning Synapses and Networks for Plasticity https://pubmed.ncbi.nlm.nih.gov/18401345/

MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34708874/

Reduction in Social Anxiety After MDMA-Assisted Psychotherapy With Autistic Adults: A Randomized, Double-Blind, Placebo-Controlled Pilot Study https://pubmed.ncbi.nlm.nih.gov/30196397/

Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex https://pubmed.ncbi.nlm.nih.gov/18508116/

Serotonin Syndrome https://emedicine.medscape.com/article/2500075-overview

Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984489). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://emedicine.medscape.com/article/288259-overview

First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/21141653/

Comprehensive Versus Usual Community Care for First Episode Psychosis: Two-Year Outcomes From the NIMH RAISE Early Treatment Program https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981493/

Schizophrenia Treatment & Management https://emedicine.medscape.com/article/288259-treatment#d9

Akinesia https://pubmed.ncbi.nlm.nih.gov/32965848/

Clozapine (Rx) https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

20-year Nationwide Follow-up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/29621900/

A Randomized, Controlled Trial of Omega-3 Fatty Acids Plus an Antioxidant for Relapse Prevention After Antipsychotic Discontinuation in First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/24996507/

Beneficial Effects of Omega-3 Fatty Acid Supplementation in Schizophrenia: Possible Mechanisms https://pubmed.ncbi.nlm.nih.gov/32620164/

An Overview of Coordinated Specialty Care (CSC) for Persons With First Episode Psychosis https://www.nasmhpd.org/content/presentation/overview-coordinated-specialty-care-csc-persons-first-episode-psychosis

Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984484). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://emedicine.medscape.com/article/288259-overview

Schizophrenia and Clinical High Risk https://www.ampscz.org/about/schizophrenia-chr/

PRIME Psychosis Prodrome Research Clinic https://medicine.yale.edu/psychiatry/research/programs/clinical_people/prodome/?locationId=460

Conversion to Psychosis in Adolescents and Adults: Similar Proportions, Different Predictors https://pubmed.ncbi.nlm.nih.gov/32248862/

Clinical Validity of DSM-5 Attenuated Psychosis Syndrome: Advances in Diagnosis, Prognosis, and Treatment https://pubmed.ncbi.nlm.nih.gov/31746950/

Prevalence of Individuals at Clinical High-risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/34827543/

Stability of Mental Disorder Prevalence Estimates Among School-aged Children and Adolescents: Findings From the Community-based Project to Learn About Youth-mental Health (PLAY-MH) and Replication-PLAY-MH (Re-PLAY-MH), 2014-2017 https://pubmed.ncbi.nlm.nih.gov/35661706/

The Clinician's Illusion https://pubmed.ncbi.nlm.nih.gov/6334503/

What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors https://pubmed.ncbi.nlm.nih.gov/31219164/

Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study https://pubmed.ncbi.nlm.nih.gov/27806157/

Accelerated Cortical Thinning Precedes and Predicts Conversion to Psychosis: The NAPLS3 Longitudinal Study of Youth at Clinical High-risk https://pubmed.ncbi.nlm.nih.gov/36434057/

Treatment Outcomes for Young People at Clinical High Risk for Psychosis: Data From a Specialized Clinic https://pubmed.ncbi.nlm.nih.gov/34309198/

Real-world Effectiveness of Antipsychotic Treatment in Psychosis Prevention in a 3-year Cohort of 517 Individuals at Clinical High Risk From the SHARP (ShangHai at Risk for Psychosis) https://pubmed.ncbi.nlm.nih.gov/32436725/

The PRIME North America Randomized Double-blind Clinical Trial of Olanzapine Versus Placebo in Patients at Risk of Being Prodromally Symptomatic for Psychosis: I. Study Rationale and Design https://pubmed.ncbi.nlm.nih.gov/12648731/

Accelerating Medicines Partnership® Program - Schizophrenia (AMP® SCZ) https://www.nimh.nih.gov/research/research-funded-by-nimh/research-initiatives/accelerating-medicines-partnershipr-program-schizophrenia-ampr-scz#:~:text=The%20Accelerating%20Medicines%20Partnership%C2%AE,multiple%20public%20and%20private%20organizations.

Drs John M. Kane and Christoph U. Correll discuss the importance of ongoing assessment of psychiatric comorbidities in patients with schizophrenia and its impact on outcomes and treatment decisions.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984483). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://www.medscape.com/resource/schizophrenia

What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications? https://www.medscape.com/viewarticle/969525

Trauma and Posttraumatic Stress Disorder (PTSD) in Patients With Schizophrenia or Schizoaffective Disorder https://pubmed.ncbi.nlm.nih.gov/19777347/

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) https://www.psychiatry.org/psychiatrists/practice/dsm

Relationship Between Obsessive Compulsive Symptomatology and Severity of Psychotic Symptoms in Schizophrenia: Meta-analysis and Meta-Regression Analysis https://pubmed.ncbi.nlm.nih.gov/36549240/

Clozapine-Induced Obsessive-Compulsive Symptoms: Mechanisms and Treatment https://pubmed.ncbi.nlm.nih.gov/30565908/

The Specific Phenotype of Depression in Recent Onset Schizophrenia Spectrum Disorders: A Symptom Profile and Network Comparison to Recent Onset Major Depressive Disorder Without Psychotic Features https://pubmed.ncbi.nlm.nih.gov/34942537/

Schizophrenia Comorbid With Panic Disorder: Evidence for Distinct Cognitive Profiles https://pubmed.ncbi.nlm.nih.gov/22417926/

Obsessive-Compulsive Disorder Comorbid With Schizophrenia and Bipolar Disorder https://pubmed.ncbi.nlm.nih.gov/30745688/

Depressive Symptoms in Schizophrenic Patients https://pubmed.ncbi.nlm.nih.gov/22112362/

Post-Psychotic Depression: An Updated Review of the Term and Clinical Implications https://pubmed.ncbi.nlm.nih.gov/35220306/

Mortality in People With Schizophrenia: A Systematic Review and Meta-analysis of Relative Risk and Aggravating or Attenuating Factors https://pubmed.ncbi.nlm.nih.gov/35524619/

Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33252130/

The RAISE Early Treatment Program for First-Episode Psychosis: Background, Rationale, and Study Design https://pubmed.ncbi.nlm.nih.gov/25830446/

First Episode Psychosis With and Without the Use of Cannabis and Synthetic Cannabinoids: Psychopathology, Global Functioning and Suicidal Ideation and Antipsychotic Effectiveness https://pubmed.ncbi.nlm.nih.gov/36682093/

Cannabis Use Among Patients With Psychotic Disorders https://pubmed.ncbi.nlm.nih.gov/35348056/

Methamphetamine Psychosis: Epidemiology and Management https://pubmed.ncbi.nlm.nih.gov/25373627/

Demographic and Clinical Correlates of Substance Use Disorders in First Episode Psychosis https://pubmed.ncbi.nlm.nih.gov/28697856/

Why Do Patients With Schizophrenia Smoke? https://pubmed.ncbi.nlm.nih.gov/20051860

Drs John M. Kane and Jose Rubio-Lorente discuss the value of long-acting injectable formulations in reducing the risk for relapse and rehospitalization for patients diagnosed with schizophrenia.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984482). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://emedicine.medscape.com/article/288259-overview

The Nature of Relapse in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/23394123/

What Is the Risk-Benefit Ratio of Long-term Antipsychotic Treatment in People With Schizophrenia? https://pubmed.ncbi.nlm.nih.gov/29856543/

Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study https://pubmed.ncbi.nlm.nih.gov/34129663/

Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia https://pubmed.ncbi.nlm.nih.gov/36791360/

Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-analysis of Mirror-Image Studies https://pubmed.ncbi.nlm.nih.gov/24229745/

Antipsychotic Use Among Persons With Schizophrenia in Sweden and Finland, Trends and Differences https://pubmed.ncbi.nlm.nih.gov/33331804/

Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-Acting Injectable Antipsychotics in Clinically Stabilized Patients With Schizophrenia: A Re-analysis of Individual Participant Data https://pubmed.ncbi.nlm.nih.gov/34355232/

Drs John M. Kane and Jonathan Meyer discuss treatment-resistant schizophrenia, how common it is, how to detect and manage it, and how delays in the initiation of treatment negatively affect patients.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

Treatment Resistant Schizophrenia: Clinical, Biological, and Therapeutic Perspectives https://pubmed.ncbi.nlm.nih.gov/30170114/

Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders https://pubmed.ncbi.nlm.nih.gov/33043960/

Mortality in People With Schizophrenia: A Systematic Review and Meta-analysis of Relative Risk and Aggravating or Attenuating Factors https://pubmed.ncbi.nlm.nih.gov/35524619/

Pharmacological Interventions for Clozapine-Induced Hypersalivation https://pubmed.ncbi.nlm.nih.gov/18646130/

The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders https://pubmed.ncbi.nlm.nih.gov/25154620/

Antipsychotic Plasma Levels in the Assessment of Poor Treatment Response in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/29072776/

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology https://pubmed.ncbi.nlm.nih.gov/27919182/

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels https://pubmed.ncbi.nlm.nih.gov/34911124/

FDA Strengthens Warning That Untreated Constipation Caused by Schizophrenia Medicine Clozapine (Clozaril) Can Lead to Serious Bowel Problems https://www.fda.gov/drugs/drug-safety-and-availability/fda-strengthens-warning-untreated-constipation-caused-schizophrenia-medicine-clozapine-clozaril-can

Cariprazine https://reference.medscape.com/drug/vraylar-cariprazine-999874

Lumateperone https://reference.medscape.com/drug/caplyta-lumateperone-1000316

Lurasidone https://reference.medscape.com/drug/latuda-lurasidone-999605

Drs John Kane and Jose Rubio-Lorente discuss relapse in schizophrenia — why it occurs, how often it occurs, and what we can do about it.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969531). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://www.medscape.com/resource/schizophrenia

Schizophrenia Clinical Presentation https://emedicine.medscape.com/article/288259-clinical

Natural Course of Schizophrenic Disorders: A 15-Year Follow-up of a Dutch Incidence Cohort https://academic.oup.com/schizophreniabulletin/article/24/1/75/1878027

Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder https://jamanetwork.com/journals/jamapsychiatry/fullarticle/204795

Five-Fold Increased Risk of Relapse Following Breaks in Antipsychotic Treatment of First Episode Psychosis https://www.sciencedirect.com/science/article/abs/pii/S0920996416304376?via%3Dihub

Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530382/

Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29,823 Patients With Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710250

Long-Acting Injectable Versus Oral Antipsychotics for the Maintenance Treatment of Schizophrenia: A Systematic Review and Comparative Meta-analysis of Randomised, Cohort, and Pre-Post Studies https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00039-0/fulltext

Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364341/

Psychosis Relapse During Treatment With Long-Acting Injectable Antipsychotics in Individuals With Schizophrenia-Spectrum Disorders: An Individual Participant Data Meta-analysis https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30264-9/fulltext

The Pharmacological Treatment of Schizophrenia: How Far Have We Come? https://onlinelibrary.wiley.com/doi/full/10.1002/pcn5.13

Striatal Functional Connectivity in Psychosis Relapse: A Hypothesis Generating Study https://www.sciencedirect.com/science/article/pii/S092099642100222X?via%3Dihub

Drs John Kane and Anil Malhotra discuss neuroimaging and connectivity between various regions of the brain in patients with schizophrenia and how it impacts the pathophysiology and treatment response.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969530). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://www.medscape.com/resource/schizophrenia

Diffusion Tensor Imaging Measures of White Matter Compared to Myelin Basic Protein Immunofluorescence in Tissue Cleared Intact Brains https://www.sciencedirect.com/science/article/pii/S235234091630779X?via%3Dihub

Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845897/

Dissecting Heterogeneity of Treatment Response of First Episode Schizophrenia https://grantome.com/grant/NIH/P50-MH080173-05

The M1/M4 Preferring Muscarinic Agonist Xanomeline Modulates Functional Connectivity and NMDAR Antagonist-Induced Changes in the Mouse Brain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115158/

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence From Preclinical Models and Clinical Studies https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704992/

ECT and Other Procedures for Schizophrenia https://www.webmd.com/schizophrenia/electroconvulsive-therapy

Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2014.13060787

Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

Psychosis Relapse During Treatment With Long-Acting Injectable Antipsychotics in Individuals With Schizophrenia-Spectrum Disorders: An Individual Participant Data Meta-analysis https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30264-9/fulltext

North American Prodrome Longitudinal Study https://napls.ucsf.edu/

Association Between Residential Instability at Individual and Area Levels and Future Psychosis in Adolescents at Clinical High Risk From the North American Prodrome Longitudinal Study (NAPLS) Consortium https://www.sciencedirect.com/science/article/abs/pii/S0920996421003959?via%3Dihub

Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2792519

Brain Disease and Psychiatric Illness: When Should a Psychiatrist Order a CAT Scan? https://ajp.psychiatryonline.org/doi/10.1176/ajp.141.12.1521

Transcranial Magnetic Stimulation for Positive Symptoms in Schizophrenia: A Systematic Review https://www.karger.com/Article/FullText/502148

Drs John Kane and Philip D. Harvey discuss how physicians can assess cognitive functioning in patients with schizophrenia and how to utilize rehabilitation and technology to address it.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969529). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Schizophrenia https://www.medscape.com/resource/schizophrenia

Schizophrenia Practice Essentials https://emedicine.medscape.com/article/288259-overview

The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.163.3.426

Comprehensive Review of the Research Employing the Schizophrenia Cognition Rating Scale (SCoRS) https://www.sciencedirect.com/science/article/pii/S0920996419302178

Using a Meta-cognitive Wisconsin Card Sorting Test to Measure Introspective Accuracy and Biases in Schizophrenia and Bipolar Disorder https://www.sciencedirect.com/science/article/abs/pii/S0022395621003903

Developing a Cognitive Training Strategy for First-Episode Schizophrenia: Integrating Bottom-Up and Top-Down Approaches https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256669/

Brain HQ https://www.brainhq.com/

Training Engagement, Baseline Cognitive Functioning, and Cognitive Gains With Computerized Cognitive Training: A Cross-Diagnostic Study https://europepmc.org/article/pmc/pmc6889599

Efficacy and Safety of the Novel Glycine Transporter Inhibitor BI 425809 Once Daily in Patients With Schizophrenia: A Double-Blind, Randomised, Placebo-Controlled Phase 2 Study https://linkinghub.elsevier.com/retrieve/pii/S2215-0366(20)30513-7

A Study to Test Long-term Safety of BI 425809 in People With Schizophrenia Who Took Part in a Previous CONNEX Study https://clinicaltrials.gov/ct2/show/NCT05211947

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients With Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105423/

Karunatx.com. KarXT https://karunatx.com/pipeline-programs/karxt/

F46. The Potential of M1 Agonists to Treat Cognitive Impairment: Evidence From a Phase 2 Study of KarXT in Schizophrenia (EMERGENT-1) https://pmg.joynadmin.org/documents/1007/6247485871767404791c9d14.pdf

Cognitive Training and Supported Employment for Persons With Severe Mental Illness: One-Year Results From a Randomized Controlled Trial https://academic.oup.com/schizophreniabulletin/article/31/4/898/1877695

Long-Acting Antipsychotic Therapies for Patients With Schizophrenia https://reference.medscape.com/recap/949130

Why Treating Early, Treating Well, and Treating for Life Is Important in Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991981/

Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496792/

P515. Genomic Analyses of Schizophrenia and Bipolar Disorder Patients With Very Poor Outcomes https://www.researchgate.net/publication/360255195_P515_Genomic_Analyses_of_Schizophrenia_and_Bipolar_Disorder_Patients_With_Very_Poor_Outcomes

Challenges in Assessment of Daytime Sleepiness in Cognitively Impaired Populations Can Be Bypassed Through Use of Ecological Momentary Assessment https://scholarship.miami.edu/esploro/outputs/report/Challenges-in-Assessment-of-Daytime-Sleepiness/991031600661502976

Evidence for Avolition in Bipolar Disorder? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141033/

Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer?

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition https://www.amazon.com/Clinical-Antipsychotic-Plasma-Levels-Psychopharmacology-ebook-dp-B09B3VMM8N/dp/B09B3VMM8N

Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1955.tb42463.x

Arvid Carlsson https://www.nobelprize.org/prizes/medicine/2000/carlsson/facts/

Clozapine: Guidelines for Clinical Management https://pubmed.ncbi.nlm.nih.gov/2670914/

Clozapine: Medscape Drugs & Diseases https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis https://www.psychiatrist.com/jcp/movement-disorder/tardive-dyskinesia-prevalence/

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities https://pubs.acs.org/doi/10.1021/acsptsci.2c00016

Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity https://jpet.aspetjournals.org/content/324/3/948.long

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa1911772

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia https://clinicaltrials.gov/ct2/show/NCT04109950

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms https://clinicaltrials.gov/ct2/show/NCT03669640

Emerging Schizophrenia Drugs Target Negative Symptoms https://www.medscape.com/viewarticle/953336

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2008.06091591

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa2017015

Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning https://www.psychiatrist.com/jcp/schizophrenia/risperidone-mgday-vs-mgday-episode-acutely-psychotic/